A new study published in JAMA Network Open reveals a significant difference in opinion regarding cannabis access between chronic pain patients and their physicians. While patients overwhelmingly support policies that expand access to medical marijuana, physicians tend to favor stricter regulations and access control.
Fzata, Inc. has been awarded a $7 million grant from the National Institutes of Health (NIH) to develop a groundbreaking oral treatment for chronic visceral pain associated with inflammatory bowel syndrome (IBS). The grant will fund pre-clinical and Phase 1 clinical trials for FZ006, a novel drug candidate based on Fzata’s BioPYMTM platform technology.
New research reveals that mindfulness meditation can effectively reduce pain perception, and it’s not just a placebo effect. Brain scans show that the practice activates specific pathways in the brain, distinct from those triggered by placebo, leading to more powerful pain relief. This discovery suggests mindfulness meditation could be a promising treatment option for chronic pain.
Bianca Padurariu, a 20-year-old nanny from London, has been suffering from a persistent urinary tract infection (UTI) for nearly three years. Despite multiple visits to her GP and rounds of antibiotics, her symptoms have not improved. She claims that during a follow-up appointment with a urologist at Queen Mary’s Hospital, the doctor suggested she use Google to find answers to her health concerns. Frustrated with the lack of help she has received from the NHS, Bianca has now given up on receiving treatment from the healthcare system and is actively fundraising to afford private treatment.
Neuronoff, a leader in neuromodulation therapies, has achieved a major milestone with the successful completion of the first-in-human clinical trial for its flagship product, the Injectrode. The study evaluated the safety and effectiveness of the Injectrode, a minimally invasive solution for chronic pain management.
